We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas.
- Authors
Dumont, M.; Ram‐Wolff, C.; Roelens, M.; Brice, P.; Peffault de Latour, R.; Battistella, M.; Madelaine, I.; Delyon, J.; Herms, F.; Bouaziz, J.‐D.; Moins‐Teisserenc, H.; Lebbé, C.; Bagot, M.; Masson, A.
- Abstract
Dear Editor, The treatment of advanced-stage cutaneous T-cell lymphomas (CTCL) is challenging and responses are usually short lived. Toxicities were observed in six of nine patients, including three severe adverse events: two patients developed severe acute renal failure (one of them had a single kidney), and one patient developed I Pneumocystis i pneumonia. Two of our patients with transformed SS had received four and six previous systemic treatment lines, respectively, and achieved a CR following B+B (22% of the whole group and 33% of patients with SS), allowing subsequent allogeneic HSCT and an ongoing CR 5 months and 1 year after transplant.
- Subjects
CUTANEOUS T-cell lymphoma; HODGKIN'S disease; HEMATOPOIETIC stem cell transplantation
- Publication
British Journal of Dermatology, 2019, Vol 181, Issue 6, p1315
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.18215